- McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: A Scientific Statement for health professionals from the American Heart Association. Circulation. 2017;135:e927-99, http://dx.doi.org/10.1161/cir.0000000000000484.
- 3. Matsubara T, Mason W, Kashani IA, et al. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr. 1996;128:701-3, http://dx.doi.org/10.1016/s0022-3476(96)80140-5.
- Zulian F, Falcini F, Zancan L, et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr. 2003;142:731-5, http://dx.doi.org/10.1067/mpd.2003.232.
- Chang CH, Chen MH, Yang W. Kawasaki disease presenting with lymphadenopathy and gastrointestinal hemorrhage: report of one case. Acta Paediatr Taiwan. 2004;45:171-3, http://dx.doi.org/10.7097/APT.200406.0171.
- Singh R, Ward C, Walton M, et al. Atypical Kawasaki disease and gastrointestinal manifestations. Paediatr Child Health. 2007;12:235-7, http://dx.doi.org/10.1093/pch/12.3.235.
- Asada D, Taura Y, Itoh H, et al. Acute gastrointestinal hemorrhage in Kawasaki disease occurring before aspirin therapy. Pediatr Int. 2019;61:1177–8, http://dx.doi.org/10.1111/ped.13989.

- Hu C, Yu Y. Gastrointestinal hemorrhage before anticoagulant therapy in Kawasaki disease: a case report. BMC Pediatr. 2020;20, http://dx.doi.org/10.1186/s12887-020-1916-6.
- C.A. González-Heredia ^{a,*}, A.Y. Martínez-Vázquez ^b, J.A. Galindo-Martínez ^b
- ^a Departamento de Pediatría, Hospital para el Niño Poblano. Puebla. Mexico
- ^b Departamento de Gastroenterología y Endoscopia Pediátrica, Hospital para el Niño Poblano, Puebla, Mexico
- *Corresponding author at: Calle 18^a Numero 179 por 23a y 23b Colonia San Pedro Cholul, Mérida C.P. 97138. Tel.: 9991151733.

E-mail address: carlosaglz@outlook.com (C.A. González-Heredia).

2255-534X/ © 2025 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Hemostatic clip use for the control of ulcer bleeding after esophageal variceal ligation



Uso de clip hemostático para el control del sangrado por úlcera posligadura de várices esofágicas

Variceal upper gastrointestinal bleeding (UGIB) is one of the complications of portal hypertension. It is associated with high morbidity and mortality at 6 weeks, in around 15-20% of patients. Endoscopic variceal ligation (EVL) plays an important role in treating said bleeds. Despite its efficacy and safety profile, the procedure can cause potentially life-threatening bleeding secondary to ulceration, following band ligation. 4,5

A 57-year-old woman had a past medical history of diabetes mellitus, high blood pressure, and Child B cirrhosis of the liver, with a MELD score of 10. She was diagnosed in 2023, when she presented with her first episode of variceal UGIB.

She was admitted to our hospital in June 2024 and programmed for EVL as an outpatient. In the gastroduodenal endoscopy (GDE), 3 large esophageal varices and one medium-sized varix were found. EVL was carried out using 3 elastic bands, with no immediate complications (Fig. 1). Ten days later, the patient arrived at the emergency service, presenting with hematemesis at a volume of 1000 cc, melena, and syncope.

Physical examination revealed that she was hemodynamically unstable, with a Glasgow coma scale score of 14. Laboratory tests showed a decrease in hemoglobin, compared with the previous outpatient control value (from 10.5 to $7.6\,\mathrm{g/dl}$).

The patient was admitted to the intensive care unit and medical management of the variceal UGIB was started. Dur-

ing the first hours of hospitalization, she presented with a new episode of hematemesis, greater hemodynamic instability, and a decrease in hemoglobin to 5.9 g/dl. She was intubated and vasopressor support was started.

GDE was performed, revealing an abundant amount of blood in the esophagus (Fig. 2A) arising from an actively bleeding post-ligation ulcer. The previously placed elastic band was becoming detached (Fig. 2B) and came completely detached during the procedure (Fig. 2C). In addition, 3 large varicose cords that were distally ligated were identified. A new ligation at the level of the post-ligation ulcer was unsuccessfully attempted. With the aid of an endoscopic cup, a hemostatic clip was placed, achieving complete hemostasis (Fig. 2D).

The patient's clinical evolution was good, and she was released after 5 days, with no complications.

The incidence of post-ligation bleeding (PLB) is from 2. 3 to 7 .3%, 3 with a mortality rate of 22.3-24.5%. 2,5

After EVL, the band remains attached to the esophageal wall for 3 to 7 days and thrombi develop in the strangulated vessels. ^{5,6} The band then detaches, resulting in an ulcer that generally heals in 2 to 3 weeks. ³ Premature detachment of the band exposes the vessel inside the ulcer, leading to PLB. ⁷ The time from EVL to PLB is an average of 11 days. ²

There is no consensus on bleed predictors after EVL.² Some studies ^{3,5,6} have found that factors associated with PLB were hepatocellular carcinoma, higher Child-Pugh score, MELD score above 10, high prothrombin time, and suboptimum dose of propranolol. In the study by Reji et al., other associated factors were peptic esophagitis and a low hemoglobin level.² Our patient had a Child B score of 7, a MELD score of 10, and mild anemia.

Other factors related to the endoscopic procedure are emergency EVL, the use of a higher number of bands, highrisk varices, larger varices, a higher number of esophageal varices, ^{8,9} and associated gastric varices.³ Of those factors, emergency EVL is the strongest predictor for PLB.




Figure 1 GDE showing 3 large varicose cords and one medium-size varix.




Figure 2 A) Abundant blood in the esophagus. B) Esophageal varix with an almost completely detached elastic band (yellow arrow) adjacent to the ulcer with a clot (arrowhead). C) Ulcer with a clot and active bleeding, now with no elastic band. D) Hemostatic clip placement, achieving hemostasis.

Cases of variceal UGIB are usually managed with intravenous vasoactive agents and proton pump inhibitors (PPIs). PPIs have been described in the literature as possibly reducing the magnitude of PLB, but different reports on PPI use found no effect on bleeding complications or mortality. ^{2–4,10} One study reported a trend toward a higher mortality rate in patients that received only PPIs. ⁶

Despite the high mortality rate, there is no standard treatment for PLB.⁶ Current treatment continues to be empiric and is based on the experience from individual centers. In a systematic review,⁵ the following were considered management options: new EVL, argon plasma coagulation, sclerotherapy, cyanoacrylate injection, epinephrine injection, HemoClip®, and Hemospray®. None of those techniques has been shown to be superior to another, and their use should be individualized, according to each case and center.

In the case of our patient, a new EVL was attempted, but despite intense aspiration, the band did not attach at that level, most likely due to the surrounding fibrosis from the previous ligations. Given the persistent active bleeding, hemostatic clip placement was decided upon, achieving complete hemostasis.

Author contributions

The authors have participated in the concept and design of the article and in the writing and approval of the final version to be published.

Ethical considerations

The authors declare that no experiments on humans were conducted for this work. We employed the patient data collection formats of our work center, maintaining patient anonymity. Informed consent was previously obtained. The authors declare that this article contains no personal information that could identify the patient. This work meets the current bioethical research norms and was authorized by our institutional ethics committee.

Financial disclosure

No financial support was received in relation to this article.

Conflict of interest

The authors declare that there is no conflict of interest.

References

- Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35, http://dx.doi.org/10.1002/hep.28906.
- Reji R, Buckley NS, Chin J, et al. Identification of highrisk individuals for bleeding from post-endoscopic variceal band ligation ulceration. J Gastroenterol Res. 2020;4:120-5, http://dx.doi.org/10.36959/621/604.
- 3. Dueñas E, Cachero A, Amador A, et al. Ulcer bleeding after band ligation of esophageal varices: risk factors and prognosis. Dig Liver Dis. 2020;52:79–83, http://dx.doi.org/10.1016/j.dld.2019.06.019.
- Drolz A, Schramm C, Seiz O, et al. Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis. Endoscopy. 2020;53:226–34, http://dx.doi.org/10.1055/a-1214-5355.
- 5. de Brito Nunes M, Knecht M, Wiest R, et al. Predictors and management of post-banding ulcer bleeding in cirrhosis: a systematic review and meta-analysis. Liver Int. 2023;43:1644–53, http://dx.doi.org/10.1111/liv.15621.
- Cho E, Jun CH, Cho SB, et al. Endoscopic variceal ligationinduced ulcer bleeding. Medicine (Baltimore). 2017;96:e7157, http://dx.doi.org/10.1097/MD.0000000000007157.
- 7. Nijhawan S, Rai RR, Nepalia S, et al. Natural history of postligation ulcers. Am J Gastroenterol. 1994;89:2281–2.
- Hu Z, Liu S, Liu T, et al. Bleeding from band ligationinduced ulcers following the treatment of esophageal varices: a retrospective case-control study. J Clin Gastroenterol. 2022;56:635–40.
- Ramirez FC, Colon VJ, Landan D, et al. The effects of the number of rubber bands placed at each endoscopic session upon variceal outcomes: a prospective, randomized study. Am J Gastroenterol. 2007;102:1372-6, http://dx.doi.org/10.1111/j.1572-0241.2007.01211.x.
- Shaheen NJ, Stuart E, Schmitz SM, et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology. 2005;41:588-94, http://dx.doi.org/10.1002/hep.20593.

S.A. Chávez-Sánchez*, L.E. Flores-Egocheaga

Servicio de Gastroenterología, Hospital Nacional Cayetano Heredia, Lima, Peru

* Corresponding author at: Dirección: Jr. Marco Nicolini128 - Dpto. 402. Lima, Peru. Tel.: (+51) 975243000. E-mail address: siomara.chavez@upch.pe (S.A. Chávez-Sánchez).

2255-534X/ © 2025 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).